S09 What's New in Male Contraception?

Program: Symposia
Clinical/Translational Session
Thursday, March 5, 2015: 9:30 AM-11:00 AM
Room 6B (San Diego Convention Center)
**This session is NOT eligible for CME credit**

Chair:
William J Bremner, MD, PHD, University of Washington, Seattle, WA

Nothing to Disclose: WJB Disclosure Not Provided: CW

Male contraception is a frustrating field where development has been slow. However, new leads are coming all the time and it is good to review the latest developments from time to time. The major learning objectives that will be delivered by the three speakers are: Stephanie T. Page, MD,PhD (University of Washington, Seattle, WA): The current state of hormonal male contraception The objective will to provide an up-to-date review of the development of male contraceptive formulations using steroids to block spermatogenesis by inhibiting the hypothalamic-pituitary-testicular axis while maintaining peripheral androgenic function. The risks and benefits as well as the prospects for approval of this contraceptive approach will be discussed. Michael G. O'Rand, PhD (Univ North Carolina): Non-hormonal approaches to male contraception Spermatozoa become mature while transiting through the epididymis. The objective is to present novel approaches to block the final maturation of spermatozoa and/or their interaction with oocytes by using non-endocrine approaches. This will allow for the development of novel, rapidly acting, non-hormonal male contraceptives. Polina Lishko, PhD (UC Berkeley): Sperm Ion Channels as Targets for Male Contraception The cell membrane of spermatozoa contains a number of channels proteins for ions such as calcium and potassium that are unique. The objective is to demonstrate how disruption of these channels deleteriously affects sperm in a cell-specific manner, thus resulting in novel, non-hormonal approaches for male contraception and providing major benefits over other methods.

9:30 AM
Stephanie T. Page, MD, PhD, Department of Medicine, University of Washington and Harborview Medical Center, Seattle, WA
Nothing to Disclose: STP
10:00 AM
Michael G. O'Rand, PhD, Cell Biology & Physiology, Univ North Carolina at Chapel Hill, Chapel Hill, NC
Disclosure: MGO: Founder, Eppin Pharma Inc.
10:30 AM
Polina V Lishko, PhD, Molecular and Cell Biology, UC Berkeley, Berkeley 94720-3200, CA
Nothing to Disclose: PVL
See more of: Symposia